Oryzon Genomics has announced its intention to carry out a capital increase worth 125 million euros, as revealed in the call for the extraordinary general meeting of shareholders that is scheduled for this month of December.
Details of the capital increase
The company has presented the relevant documentation for this meeting before the National Securities Market Commission (CNMV) today. The meeting is expected to take place on second call on December 12, 2025.
Approval process
At the meeting, shareholders will be asked to authorize a capital increase through cash contributions, excluding pre-emptive subscription rights. The board of directors will be given the authority to determine the date, issue price and conditions of the capital increase.
Remuneration policy and incentive plans
In addition to the capital increase, the meeting will discuss and approve the new remuneration policy for directors, which will govern during the years 2026, 2027 and 2028. A long-term incentive plan for managers and key personnel, including the executive president, will also be put to the vote.
Long-term fixed remuneration plan
The company will present for the board’s consideration the approval of a long-term fixed remuneration plan based on shares, with the aim of attracting talent and rewarding the independent directors of the board.